<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03870230</url>
  </required_header>
  <id_info>
    <org_study_id>OPHT-010213</org_study_id>
    <nct_id>NCT03870230</nct_id>
  </id_info>
  <brief_title>Investigation of Neurovascular Coupling in Glaucoma Patients and Healthy Subjects</brief_title>
  <official_title>Investigation of Neurovascular Coupling in Glaucoma Patients and Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University of Vienna</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medical University of Vienna</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Glaucoma is characterized by a progressive loss of retinal ganglion cells (RGCs) leading to&#xD;
      optic nerve head (ONH) damage and associated visual field defects. The main risk factor for&#xD;
      glaucoma is elevated intraocular pressure (IOP). Reducing IOP slows down the progression of&#xD;
      the disease as several large multicenter trials have shown. Some patients, however, still&#xD;
      progress despite adequately controlled IOP. As such, there is considerable interest in&#xD;
      approaches that rescue RGCs independent of IOP, a strategy called neuroprotection. Although&#xD;
      this field was actively discovered in the last 20 years in the brain and the eye, no non-IOP&#xD;
      related treatment is clinically available to date. Various approaches are currently studied&#xD;
      in some detail. One interesting strategy focuses on the neurovascular unit.&#xD;
&#xD;
      The blood flow of the human retina is controlled by complex mechanisms that include myogenic,&#xD;
      metabolic and hormonal factors. The high consumption of oxygen in the human retina is crucial&#xD;
      for normal functioning of the organ. As in the brain, blood flow in the retina is also&#xD;
      controlled by neurovascular coupling. This means that the retina increases its blood flow to&#xD;
      regions in which neurons are activated. This is done in an effort to provide more oxygen and&#xD;
      glucose to the active neurons. In the recent years evidence has accumulated that astrocytes&#xD;
      play a key role in mediating this vasodilator signal.&#xD;
&#xD;
      In the brain, abnormalities in neurovascular coupling have been observed in diseases like&#xD;
      stroke, hypertension, spinal-cord injury and Alzheimer's disease. This break-down of&#xD;
      neurovascular coupling is considered to play a key role in neuronal death in these diseases.&#xD;
      In the retina, abnormalities in neurovascular coupling have been observed in diseases as&#xD;
      diabetes and glaucoma.&#xD;
&#xD;
      Most of the data obtained in the human retina stem from a system that measures retinal&#xD;
      vasodilatation during stimulation with flickering light. The investigators have previously&#xD;
      shown that flicker stimulation of the retina is, however, also associated with a pronounced&#xD;
      increase in retinal blood velocities. In this study the investigators employed laser Doppler&#xD;
      velocimetry (LDV) for the measurement of retinal blood velocities, but this technique is not&#xD;
      clinically applicable because it requires excellent fixation of the subject under study. In&#xD;
      the present study, the investigators propose to use an alternative system for neurovascular&#xD;
      coupling that they have developed recently. In this approach, the investigators use&#xD;
      bi-directional Fourier-domain optical coherence tomography for the assessment of retinal&#xD;
      blood flow. Optical coherence tomography (OCT) is a non-invasive optical imaging modality&#xD;
      enabling cross-sectional tomographic in vivo visualization of internal microstructure in&#xD;
      biological systems. In ophthalmology, OCT has become a standard tool in visualizing the&#xD;
      retina and nowadays is considered also as a standard tool in the diagnosis of retinal&#xD;
      disease. In the recent years, conventional time domain OCT was replaced by Fourier domain OCT&#xD;
      providing significantly improved signal quality.&#xD;
&#xD;
      This bidirectional system overcomes the limitations of previously realized techniques, which&#xD;
      include doubtful validity and limited reproducibility. In addition, pattern ERG, multifocal&#xD;
      ERG and oscillatory potentials will be measured to allow for concomitant assessment of neural&#xD;
      function.&#xD;
&#xD;
      The investigators seek to measure neurovascular coupling in the human retina in patients with&#xD;
      early primary open angle glaucoma (POAG), normal tension glaucoma, ocular hypertension and a&#xD;
      healthy control group. In order to obtain information on neurovascular coupling, both&#xD;
      neuronal function as well as retinal blood flow need to be measured. In the present study,&#xD;
      the investigators will employ pattern ERG, multifocal ERG as well as oscillatory potentials&#xD;
      to assess the function of the inner retina. Retinal blood flow through major retinal arterial&#xD;
      and venous branch vessels will be measured before, during and after flicker stimulation with&#xD;
      the dual-beam bidirectional Fourier Domain Doppler OCT coupled to the commercially available&#xD;
      Dynamic Vessel Analyzer (DVA) produced by IMEDOS, Jena, Germany, which provides adequate&#xD;
      resolution to study the retinal circulation.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 1, 2017</start_date>
  <completion_date type="Anticipated">March 2022</completion_date>
  <primary_completion_date type="Anticipated">March 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Flicker induced blood flow alterations</measure>
    <time_frame>1 day</time_frame>
    <description>Response of retinal blood flow to flicker light</description>
  </primary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Glaucoma, Open-Angle</condition>
  <condition>Normal Tension Glaucoma</condition>
  <condition>Ocular Hypertension</condition>
  <arm_group>
    <arm_group_label>POAG MD&lt;10dB</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>patients with primary open angle glaucoma with MD in visual field less than or equal 10dB</description>
  </arm_group>
  <arm_group>
    <arm_group_label>POAG MD&gt;10dB</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>patients with primary open angle glaucoma with MD in visual field more than 10dB</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NTG MD&lt;10dB</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>patients with normal tension glaucoma with MD in visual field less than or equal 10dB</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NTG MD&gt;10dB</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>patients with normal tension glaucoma with MD in visual field more than 10dB</description>
  </arm_group>
  <arm_group>
    <arm_group_label>OHT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>patients with ocular hypertension</description>
  </arm_group>
  <arm_group>
    <arm_group_label>controls</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>healthy, age and sex matched, control subjects</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Fourier Domain Doppler Optical Coherence Tomography (FDOCT)</intervention_name>
    <description>Retinal blood flow will be assessed using FDOCT</description>
    <arm_group_label>NTG MD&lt;10dB</arm_group_label>
    <arm_group_label>NTG MD&gt;10dB</arm_group_label>
    <arm_group_label>OHT</arm_group_label>
    <arm_group_label>POAG MD&lt;10dB</arm_group_label>
    <arm_group_label>POAG MD&gt;10dB</arm_group_label>
    <arm_group_label>controls</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Dynamic Vessel Analyzer (DVA)</intervention_name>
    <description>Retinal vessel diameters and oxygen saturation will be measured with the DVA device</description>
    <arm_group_label>NTG MD&lt;10dB</arm_group_label>
    <arm_group_label>NTG MD&gt;10dB</arm_group_label>
    <arm_group_label>OHT</arm_group_label>
    <arm_group_label>POAG MD&lt;10dB</arm_group_label>
    <arm_group_label>POAG MD&gt;10dB</arm_group_label>
    <arm_group_label>controls</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Pattern Electroretinography (pERG)</intervention_name>
    <description>to assess the neuronal function of the retina, pattern ERG will be performed</description>
    <arm_group_label>NTG MD&lt;10dB</arm_group_label>
    <arm_group_label>NTG MD&gt;10dB</arm_group_label>
    <arm_group_label>OHT</arm_group_label>
    <arm_group_label>POAG MD&lt;10dB</arm_group_label>
    <arm_group_label>POAG MD&gt;10dB</arm_group_label>
    <arm_group_label>controls</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Optical coherence tomography (OCT)</intervention_name>
    <description>to assess the morphology of the retina, OCT will be performed</description>
    <arm_group_label>NTG MD&lt;10dB</arm_group_label>
    <arm_group_label>NTG MD&gt;10dB</arm_group_label>
    <arm_group_label>OHT</arm_group_label>
    <arm_group_label>POAG MD&lt;10dB</arm_group_label>
    <arm_group_label>POAG MD&gt;10dB</arm_group_label>
    <arm_group_label>controls</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Laser Speckle Flowgraphy (LSFG)</intervention_name>
    <description>to assess retinal blood flow, LSFG will be performed</description>
    <arm_group_label>NTG MD&lt;10dB</arm_group_label>
    <arm_group_label>NTG MD&gt;10dB</arm_group_label>
    <arm_group_label>OHT</arm_group_label>
    <arm_group_label>POAG MD&lt;10dB</arm_group_label>
    <arm_group_label>POAG MD&gt;10dB</arm_group_label>
    <arm_group_label>controls</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria&#xD;
&#xD;
        Patients with primary open angle glaucoma&#xD;
&#xD;
          -  Diagnosis of manifest primary open angle glaucoma defined as pathological optic disc&#xD;
             appearance&#xD;
&#xD;
          -  Glaucoma hemifield test outside normal limits&#xD;
&#xD;
          -  Untreated IOP ≥ 21 mmHg on at least three measurements in the medical history&#xD;
&#xD;
          -  Mean deviation in the visual field test is less than or equal 10dB (for one group) OR&#xD;
             more than 10dB (for the other group)&#xD;
&#xD;
        Patients with normal tension glaucoma&#xD;
&#xD;
          -  Diagnosis of manifest normal tension glaucoma defined as pathological optic disc&#xD;
             appearance&#xD;
&#xD;
          -  Glaucoma hemifield test outside normal limits&#xD;
&#xD;
          -  No evidence of untreated IOP &gt; 20 mmHg in the medical history&#xD;
&#xD;
          -  Mean deviation in the visual field is less than or equal 10dB (for one group) OR more&#xD;
             than 10dB (for the other group)&#xD;
&#xD;
        Patients with ocular hypertension&#xD;
&#xD;
          -  Normal ophthalmic findings except presence of ocular hypertension defined as untreated&#xD;
             IOP ≥ 21 mmHg on at least three measurements in the medical history&#xD;
&#xD;
          -  No signs of glaucomatous damage in the optic disc&#xD;
&#xD;
          -  or the glaucoma hemifield test&#xD;
&#xD;
        Healthy control subjects&#xD;
&#xD;
          -  Normal ophthalmic findings&#xD;
&#xD;
          -  IOP &lt; 20 mmHg on least three measurements&#xD;
&#xD;
          -  No evidence of increased IOP in the medical history&#xD;
&#xD;
          -  No signs of glaucomatous damage in the optic disc&#xD;
&#xD;
          -  or the glaucoma hemifield test&#xD;
&#xD;
        Exclusion criteria&#xD;
&#xD;
          -  History of a severe medical condition as judged by the clinical investigator&#xD;
&#xD;
          -  Abuse of alcoholic beverages&#xD;
&#xD;
          -  Smoker&#xD;
&#xD;
          -  Participation in a clinical trial in the 3 weeks preceding the study&#xD;
&#xD;
          -  Exfoliation glaucoma, pigmentary glaucoma, history of acute angle closure&#xD;
&#xD;
          -  Intraocular surgery within the last 6 months&#xD;
&#xD;
          -  Ocular inflammation or infection within the last 3 months&#xD;
&#xD;
          -  History of epilepsia&#xD;
&#xD;
          -  Diabetes mellitus&#xD;
&#xD;
          -  Untreated hypertension with systolic blood pressure &gt; 160 mmHg, diastolic blood&#xD;
             pressure &gt; 95 mmHg&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Planned pregnancy or lactating&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gerhard Garhöfer, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Clinical Pharmacology, Medical University of Vienna</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Gerhard Garhöfer, MD</last_name>
    <phone>004314040029810</phone>
    <email>gerhard.garhoefer@meduniwien.ac.at</email>
  </overall_contact>
  <location>
    <facility>
      <name>Department of Clinical Pharmacology, Medical University of Vienna</name>
      <address>
        <city>Vienna</city>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gerhard Garhöfer, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Austria</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>March 8, 2019</study_first_submitted>
  <study_first_submitted_qc>March 8, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 12, 2019</study_first_posted>
  <last_update_submitted>May 26, 2021</last_update_submitted>
  <last_update_submitted_qc>May 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Medical University of Vienna</investigator_affiliation>
    <investigator_full_name>Gerhard Garhofer</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glaucoma</mesh_term>
    <mesh_term>Ocular Hypertension</mesh_term>
    <mesh_term>Glaucoma, Open-Angle</mesh_term>
    <mesh_term>Low Tension Glaucoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

